JPRN-jRCT2080222535未知1 期
Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients with Advanced Solid Malignant Tumors
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 57 人开始时间: 2014年6月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.
- •-Eastern Cooperative Oncology Group Performance Status of 0 or 1
排除标准
- •-Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment:
- •Cardiac failure (NYHA >= ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, uncontrolled deep-vein thrombosis or clinically severe thromboembolic event, autoimmune disorders requiring treatment.
- •-Severe or uncontrolled concomitant disease.
- •-Clinically active brain metastases defined as symptomatic or requiring treatment.
研究者
相似试验
未知
1 期
Phase 1 Study of U3-1565Solid Cancer not curable with, or not eligible for standard treatment(s)JPRN-jRCT2080221445DAIICHISANKYO Co.,Ltd.44
已完成
1 期
A clinical study to assess the safety, tolerability & immunogenicity of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children.CTRI/2022/03/040874Biological E Limited24
已完成
1 期
A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Japanese Paediatric Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable and Symptomatic Plexiform Neurofibromas (PN)JPRN-jRCT2080225326AstraZeneca KK9
已完成
1 期
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080225373AstraZeneca KK12
进行中（未招募）
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients with Advanced Solid MalignanciesAdvanced solid malignanciesJPRN-jRCT2031220106Yamaji Shigeyuki18